Posted: 1 July 2024
BioMelbourne Network, the peak body in the Victorian healthtech industry, is pleased to announce the appointment of five new Directors and Treasurer to its Board, effective from 1 July 2024.
These appointments refill the Association’s Board with highly experienced ecosystem leaders who represent the diversity present in the end-to-end Victorian healthtech ecosystem, and will provide strategic guidance as the Association actively fosters and grows the local innovative and globally competitive sector.
The new Treasurer and Board Director appointments include:
- Dr Irene Kourtis, BioMelbourne Network Treasurer and Managing Director, RISE Advisory Group
- Dr Emma Ball, Head of Ecosystem Development, Illumina
- Professor Ian Meredith AM, Vice Chancellor’s Professorial Fellow, Monash University; and Non-Executive Director
- Professor Vera Ignjatovic, Associate Director for Translational Research, Johns Hopkins All Children’s Institute for Clinical and Translational Research; and Professor of Paediatrics, Johns Hopkins University
- Dr Alison Greenway, Senior Director Enterprise and Partnerships, Monash University.
On behalf of the Board, BioMelbourne Network Chair David Herd said: “Welcome to our new Directors who bring a depth of experience on boards and in leadership roles across our sector.”
“Our expanded Board of 11 directors is well placed to support our CEO Karen Parr and diverse membership, and also transform our Network.”
Dr Irene Kourtis has served as a Treasurer at the Forensic and Clinical Toxicology Association Inc, member of the Melbourne Genomics Health Alliance Board and Non-Executive Director at Cytonics Australia Pty Ltd.
Dr Emma Ball has served as a Non-Executive Director at Startup Shakeup Ltd, Life Sciences Member and Advisor at SBE Australia, as a member of the AusBiotech Victorian Committee and Guest of the Chair at MTPConnect (board observer role).
Professor Ian Meredith AM has served as a Non-Executive Director on boards of Australian and US medtech companies; North American Medtech Business Ambassador to the Victorian Government; and as Executive Vice President and Global Chief Medical Officer at Boston Scientific Corporation, in the US, where he led clinical innovation, pre-clinical science and medical affairs, and provided executive leadership on clinical strategy.
Dr Alison Greenway has significant experience leading biomedical and public health business development activities in universities and medical research institutes.
Professor Vera Ignjatovic is a Director of the Toyota Community Foundation Australia and Trustee of the Toyota Community Trust, holds leadership roles at the Human Proteome Organisation and International Society on Thrombosis and Haemostasis, and has served as a Director at the Australian Society for Medical Research.
The full BioMelbourne Network Board line-up includes:
- David Herd, Chair
- Dr Elane Zelcer, Deputy Chair
- Dr Irene Kourtis, Treasurer
- Stefanie Mackenzie, Secretary/Public Officer
- Dr Emma Ball, Director
- Dr Alison Greenway, Director
- Professor Vera Ignjatovic, Director
- Dr Keith McLean, Director
- Professor Ian Meredith AM, Director
- Dr Tim Oldham, Director
- Andrew Wear, Director.
Learn more about all current members of the BioMelbourne Network Board.
–ENDS –
Media Enquiries: Vicki Burkitt, Communications Manager, BioMelbourne Network, vburkitt@biomelbourne.org.
About BioMelbourne Network
BioMelbourne Network is the peak body in the Victorian healthtech industry, driving engagement and growth in research, innovation, commercialisation and manufacturing through local and international networks. Since 2001, it has been actively fostering and growing an innovative, globally competitive sector and transforming its Network as well as the broader Victorian ecosystem. Its members are diverse and experts in their respective fields, from early-career researchers to company executives and experienced directors, and start-ups through to large multinational corporations. It represents universities, researchers, manufacturers, government departments, and the services sector, which includes commercialisation, product design and development, intellectual property, investment and legal sectors.
